Schroder Investment Management Group’s Janux Therapeutics JANX Stock Holding History

Schroder Investment Management Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54M	Sell	195,160 -71,891	-27%	-$986K	﹤0.01%	887
2025 Q4	$3.69M	Sell	267,051 -31,827	-11%	-$749K	﹤0.01%	804
2025 Q3	$7.08M	Buy	298,878 +51,962	+21%	+$1.27M	0.01%	720
2025 Q2	$5.7M	Buy	246,916 +54,544	+28%	+$1.44M	﹤0.01%	744
2025 Q1	$5.6M	Buy	192,372 +35,498	+23%	+$1.34M	0.01%	742
2024 Q4	$8.24M	Buy	156,874 +82,601	+111%	+$4.37M	0.01%	684
2024 Q3	$3.44M	Buy	74,273 +39,092	+111%	+$1.7M	﹤0.01%	861
2024 Q2	$1.47M	Buy	+35,181	New	+$1.65M	﹤0.01%	973

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Schroder Investment Management Group's JANX Position: Q1 2026 in Review

Schroder Investment Management Group reduced its Janux Therapeutics (JANX) stake by 27% in Q1 2026, selling an estimated $986K and leaving 195,160 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Schroder Investment Management Group first reported a position in JANX in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.24M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Schroder Investment Management Group held 195,160 shares of Janux Therapeutics worth $2.54M as of Q1 2026.
Schroder Investment Management Group sold 71,891 Janux Therapeutics shares in Q1 2026, an estimated $986K.
Janux Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #887 holding.
Schroder Investment Management Group first reported a position in Janux Therapeutics in Q2 2024 and has held it in 8 quarters since.
Schroder Investment Management Group's Janux Therapeutics position peaked at $8.24M in Q4 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.